A Unified Patent Court injunction forces iHerb and Pendulum to cease sales of specific products in key European markets, marking a significant legal victory for Caelus Health.
The Unified Patent Court has issued a summary injunction against iHerb, prohibiting the sale of products containing the specific bacterium for patented uses across several European nations. This legal restriction directly curtails iHerb's distribution capabilities in key markets including Germany, France, and Italy, posing a significant operational hurdle.
The injunction covers Belgium, Denmark, Germany, France, Italy, the Netherlands, Sweden, and Switzerland.
The Unified Patent Court's decision to grant a summary injunction in favor of Caelus Health validates their patent claims regarding the use of specific bacteria. By successfully blocking competitors like iHerb and Pendulum from selling infringing products, Caelus Health effectively secures its intellectual property moat and strengthens its competitive standing in the European market.
The ruling provides a provisional monopoly by forcing competitors to stop selling products that utilize Caelus Health's patented bacterial use.
The Unified Patent Court has issued a preliminary injunction against iHerb and Pendulum, halting the sale of specific bacterial products across several European markets. This ruling bolsters the patent position of Caelus Health, which successfully challenged the distribution of competing products in the region.
The court issued the injunction to protect Caelus Health's patent rights, prohibiting iHerb and Pendulum from selling products containing specific bacteria for patented uses in European markets.